Literature DB >> 26790539

Perinatal outcome in singleton pregnancies complicated with preeclampsia and eclampsia in Ecuador.

K Y N Phoa1, P Chedraui2,3, F R Pérez-López4, J F Wendte5, S Ghiabi1, T Vrijkotte5, P Pinto6.   

Abstract

Preeclampsia in Ecuador is an understudied subject since available epidemiological data are scarce. The aim of this study was to describe perinatal outcomes among singleton pregnancies complicated with preeclampsia and eclampsia in a sample of low-income Ecuadorian women. Pregnant women complicated with preeclampsia (mild and severe) and eclampsia (defined according to criteria of the ACOG) delivering at the Enrique C. Sotomayor Obstetrics and Gynecology Hospital, Guayaquil, Ecuador were surveyed with a structured questionnaire containing maternal (socio-demographic) and neonatal data. Perinatal outcomes were compared according to severity of clinical presentation. A total of 163 women with preeclampsia [mild (23.9%), severe (68.7%) and eclampsia (7.4%)] were surveyed. Perinatal mortality and stillbirth rate was similar among studied groups (mild vs. severe preeclampsia/eclampsia cases). However, severe cases displayed higher rates of adverse perinatal outcomes: lower birth Apgar scores, more preterm births, and more low birth weight and small for gestational age infants. Caesarean-section rate and the number of admissions to intensive or intermediate neonatal care were higher in severe cases. A similar trend was found when analysis excluded preterm gestations. In conclusion, in this specific low-income Ecuadorian population perinatal outcome was adverse in pregnancies complicated with severe preeclampsia/eclampsia.

Entities:  

Keywords:  Ecuador; Preeclampsia; eclampsia; low income; perinatal mortality; perinatal outcome

Mesh:

Year:  2016        PMID: 26790539     DOI: 10.3109/01443615.2015.1107532

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  7 in total

1.  RhoGDI1 interacts with PHLDA2, suppresses the proliferation, migration, and invasion of trophoblast cells, and participates in the pathogenesis of preeclampsia.

Authors:  Guiyu Song; Feng Jin
Journal:  Hum Cell       Date:  2022-07-16       Impact factor: 4.374

2.  Clinical characteristics of fetal and neonatal outcomes in twin pregnancy with preeclampsia in a retrospective case-control study: A STROBE-compliant article.

Authors:  Ting Yuan; Wei Wang; Xue-Lan Li; Chun-Fang Li; Chao Li; Wen-Li Gou; Zhen Han
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

3.  Pregnancy outcomes in younger and older adolescent mothers with severe preeclampsia.

Authors:  Priscila E Parra-Pingel; Luis A Quisiguiña-Avellán; Luis Hidalgo; Peter Chedraui; Faustino R Pérez-López
Journal:  Adolesc Health Med Ther       Date:  2017-06-06

4.  Placenta-derived extracellular vesicles induce preeclampsia in mouse models.

Authors:  Cha Han; Chenyu Wang; Yuanyuan Chen; Jiwei Wang; Xin Xu; Tristan Hilton; Wei Cai; Zilong Zhao; Yingang Wu; Ke Li; Katie Houck; Li Liu; Anil K Sood; Xiaoping Wu; Fengxia Xue; Min Li; Jing-Fei Dong; Jianning Zhang
Journal:  Haematologica       Date:  2019-08-22       Impact factor: 9.941

Review 5.  Syncytiotrophoblast-Derived Extracellular Vesicles in Pathophysiology of Preeclampsia.

Authors:  Cha Han; Lulu Han; Pengzhu Huang; Yuanyuan Chen; Yingmei Wang; Fengxia Xue
Journal:  Front Physiol       Date:  2019-10-01       Impact factor: 4.566

6.  Healthcare professionals' experiences and perceptions regarding health care of indigenous pregnant women in Ecuador.

Authors:  Tannia Valeria Carpio-Arias; Nervo Verdezoto; Marta Guijarro-Garvi; Victoria Abril-Ulloa; Nicola Mackintosh; Parisa Eslambolchilar; María Teresa Ruíz-Cantero
Journal:  BMC Pregnancy Childbirth       Date:  2022-02-04       Impact factor: 3.007

7.  Int6/eIF3e Silencing Promotes Placenta Angiogenesis in a Rat Model of Pre-eclampsia.

Authors:  Qin Li; Baolin Yao; Alexander Endler; Li Chen; Futoshi Shibasaki; Haidong Cheng
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.